Cargando…

Retrospective analysis of dermatologic adverse events associated with hydroxychloroquine reported to the US Food and Drug Administration

Detalles Bibliográficos
Autores principales:	Lipner, Shari R., Wang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American Academy of Dermatology, Inc. 2020
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345368/ https://www.ncbi.nlm.nih.gov/pubmed/32652194 http://dx.doi.org/10.1016/j.jaad.2020.07.007

Ejemplares similares

Retrospective analysis of smell and taste disturbances associated with dermatologic medications reported to the United States Food and Drug Administration and relevance to COVID-19 infections
por: Wang, Yu, et al.
Publicado: (2020)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
por: Wang, Yu, et al.
Publicado: (2020)

Dermatologic manifestations of hydroxychloroquine therapy: A closer look at the nails
por: Lipner, Shari R., et al.
Publicado: (2020)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

Analysis of skin color in the American Academy of Dermatology basic dermatology curriculum
por: Chang, Michelle J., et al.
Publicado: (2021)

The US Food and Drug Administration’s Intersection with Dermatology
por: Luke, Markham C.
Publicado: (2022)

Retrospective study of trends in dermatology telemedicine and in-person visits at an academic center during COVID-19
por: Miller, Rhiannon C., et al.
Publicado: (2021)

Analysis of availability of online dermatology appointments during the COVID-19 pandemic
por: Gu, Lilly, et al.
Publicado: (2021)

Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017
por: Dores, Graça M., et al.
Publicado: (2019)

Novel solutions for dermatologic care of geriatric patients and the role of the dermatology house call
por: Lipner, Shari R., et al.
Publicado: (2020)

Cross‐sectional study of gender and ethnicity patterns in leadership in the American Academy of Dermatology
por: Parra, Cindy E., et al.
Publicado: (2021)

Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database
por: Falotico, Julianne M., et al.
Publicado: (2022)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
por: Wang, Jun, et al.
Publicado: (2023)

Adverse Events Associated with Use of Digoxin Immune Fab Reported to the US Food and Drug Administration Adverse Event Reporting System, 1986–2019
por: Wei, Shaokui, et al.
Publicado: (2021)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
por: Zhang, Ying, et al.
Publicado: (2023)

Authors’ Reply to Michael Auerbach’s Comment on: “Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System”
por: Trumbo, Henry, et al.
Publicado: (2021)

Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, Olumiant, and Rinvoq to the US Food and Drug Administration
por: Qian, Jingjing, et al.
Publicado: (2022)

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)
por: Hoffman, Keith B., et al.
Publicado: (2014)

Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis
por: Zhou, Zeyun, et al.
Publicado: (2020)

Dermatology Receives Fewer Grants Versus Other Specialties but Excels in Citation Impact in a Cross-sectional Analysis of R01 Grants 2000–2022
por: Conway, Jade, et al.
Publicado: (2023)

Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database
por: Nagai, Junko, et al.
Publicado: (2021)

Psychiatric adverse events with hydroxychloroquine during COVID-19 pandemic
por: Emmanuel, Stip, et al.
Publicado: (2020)

Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system
por: Zhou, Yangzhong, et al.
Publicado: (2021)

Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
por: Putzke, Joerg, et al.
Publicado: (2021)

Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy
por: Ricardo, Jose W., et al.
Publicado: (2020)

Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis
por: Matsumoto, Kiyoka, et al.
Publicado: (2020)

Cosmetics and Cancer: Adverse Event Reports Submitted to the Food and Drug Administration
por: Jacob, Saya L, et al.
Publicado: (2018)

The Significance of Information Posted on the U.S. Food and Drug Administration’s Website
por: Cook, G. Elliott, et al.
Publicado: (2013)

Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS)
por: Nango, Daisuke, et al.
Publicado: (2019)

Injection-Site Nodules Associated With the Use of Exenatide Extended-Release Reported to the U.S. Food and Drug Administration Adverse Event Reporting System
por: Jones, S. Christopher, et al.
Publicado: (2015)

Analysis of 408 Total Ankle Arthroplasty Adverse Events Reported to the US Food and Drug Administration from 2015-2018
por: Chen, Jie, et al.
Publicado: (2020)

Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration’s Adverse Event Reporting System Narratives
por: Polepalli Ramesh, Balaji, et al.
Publicado: (2014)

Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-Word Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System
por: Yang, Hui, et al.
Publicado: (2022)

Mortality and oral anticoagulants in the Food and Drug Administration Adverse Event Reporting System
por: Serebruany, Victor, et al.
Publicado: (2017)

Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System
por: Trumbo, Henry, et al.
Publicado: (2020)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database
por: Toki, Tadashi, et al.
Publicado: (2018)

Dermatologic surgery during the COVID-19 pandemic: Experience of a large academic center
por: Tee, Michael W., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ua049oh1v9t3sph89je6pomsts